Aardvark Therapeutics’ (AARD) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note published on Tuesday morning,Benzinga reports. They currently have a $26.00 price objective on the stock.

Several other analysts have also issued reports on AARD. Oppenheimer initiated coverage on shares of Aardvark Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $35.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Aardvark Therapeutics in a report on Monday. B. Riley Financial assumed coverage on shares of Aardvark Therapeutics in a research report on Wednesday, January 28th. They set a “buy” rating and a $32.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Aardvark Therapeutics in a research report on Friday, November 14th. Finally, Royal Bank Of Canada decreased their price target on Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.64.

Aardvark Therapeutics Price Performance

NASDAQ:AARD opened at $12.28 on Tuesday. The company’s fifty day moving average price is $13.92 and its 200-day moving average price is $12.16. Aardvark Therapeutics has a 1-year low of $4.88 and a 1-year high of $19.58. The firm has a market capitalization of $267.34 million and a P/E ratio of -5.79.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.07.

Insider Activity

In other Aardvark Therapeutics news, CEO Tien-Li Lee acquired 7,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average price of $14.48 per share, for a total transaction of $101,360.00. Following the completion of the acquisition, the chief executive officer directly owned 1,551,613 shares of the company’s stock, valued at $22,467,356.24. This trade represents a 0.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Nelson Sun acquired 3,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were bought at an average cost of $14.40 per share, with a total value of $43,200.00. Following the purchase, the chief financial officer owned 108,484 shares in the company, valued at approximately $1,562,169.60. The trade was a 2.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Aardvark Therapeutics during the second quarter worth $42,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Aardvark Therapeutics during the 4th quarter worth about $47,000. New York State Common Retirement Fund acquired a new position in shares of Aardvark Therapeutics during the second quarter valued at about $99,000. MetLife Investment Management LLC bought a new stake in shares of Aardvark Therapeutics in the fourth quarter valued at about $102,000. Finally, Bank of America Corp DE grew its position in Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after buying an additional 3,369 shares in the last quarter.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.